CLINICAL STUDY RESULTS
A Study about Ravulizumab and Eculizumab in Patients
with Paroxysmal Nocturnal Hemoglobinuria (PNH)
who were being Treated with Eculizumab
THANK YOU!
Alexion would like to thank
all of the patients, their families, and
caregivers who took part in this
clinical study. Taking part in studies
like this one contributes directly to
the discovery of new medicines for
people with PNH.
STUDY IDENTIFICATION INFORMATION
TREATMENTS STUDIED: 1) ravulizumab, also known as ALXN1210 (trade name: Ultomiris®)
2) eculizumab (trade name: Soliris®)
STUDY TITLE: A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus
Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Currently Treated with Eculizumab.
STUDY NUMBERS: Europe, 2016-002026-36 | United States, NCT03056040 | Protocol, ALXN1210-PNH-302
© Certara USA, Inc. 2020. All rights reserved 1